Phase II Evaluation of Irinotecan (CPT-11) in Previously Treated Advanced Sarcomas
OBJECTIVES: I. Evaluate the efficacy of irinotecan in patients with metastatic, recurrent,
or unresectable locally advanced previously treated soft tissue sarcoma. II. Assess the
clinical and laboratory toxic effects and patient tolerance of this regimen in these
patients.
OUTLINE: Patients receive irinotecan IV over 90 minutes weekly for 4 weeks, followed by 2
weeks of rest. Treatment continues every 6 weeks in the absence of disease progression or
unacceptable toxicity. Patients are followed every 3 months for the first two years, then
every 6 months for the next two years, and every 12 months thereafter until death.
PROJECTED ACCRUAL: A total of 14-27 patients will be accrued for this study in 18-36 months.
Interventional
Primary Purpose: Treatment
Robert N. Taub, MD, PhD
Study Chair
Herbert Irving Comprehensive Cancer Center
United States: Federal Government
CDR0000066828
NCT00003719
July 1997
Name | Location |
---|---|
Herbert Irving Comprehensive Cancer Center | New York, New York 10032 |